CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006

PR Newswire
October 30, 2018 — 10:28 CST

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

Related Topics: army Australia Beijing China chinese healthcare medicine military pharmaceutical PLA Signal Suzhou venture capital

Related News:

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

September 14, 2024 — 08:18

Desay Battery Highlights Advanced Energy Solutions at RE+ 2024

September 11, 2024 — 03:00

Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results

August 29, 2024 — 14:31

Telin and Indosat Ooredoo Hutchison Partner to Develop the Indonesia Cable System Express 2 (ICE System 2)

August 28, 2024 — 20:46

2024 Belt and Road Journalists Forum to Be Held in Chongqing

August 25, 2024 — 17:50

Docquity and Vietnam Association of Preventive Medicine (VAPM) Partner to Advance Medical Training

August 21, 2024 — 10:00

2024 World Life Science Conference Scheduled for October 19 in Hainan, China

August 18, 2024 — 20:20

PRA Group Leader Wins Silver Stevie Award in 2024 International Business Awards

August 16, 2024 — 06:31

Ubie and the American Kidney Fund Collaborate to Speed Early Diagnosis and Education for Kidney Disease

July 19, 2024 — 00:00

Franchising and Licensing Asia (FLAsia) 2024